Fuad El Rassi
- Department of Hematology and Medical Oncology
Associate Professor
- (404) 778-1480
- fuad.elrassi@emory.edu
Overview
A board certified hematologist, Dr. El Rassi treats patients with sickle cell anemia and other blood disorders. He leads the sickle cell research program at Grady Health System, where investigational agents and curative treatments are being considered in phase I, II and III clinical trials. Additionally, Dr. El Rassi treats patients in benign hematology at Emory University Hospital Midtown.
Dr. El Rassi is a member of the Discovery and Developmental Therapeutics Research Program at Winship Cancer Institue. He is a board member and serves as treasurer for the Sickle Cell Adult Provider Network. He is also involved in hematology and medical oncology fellows' training and education in benign hematology and chairs the Fellowship Competency Committee.
Dr. El Rassi received his Medical Degree from the American University of Beirut in Beirut, Lebanon. His postgraduate medical training included a residency in internal medicine at Saint Louis University Hospital and a fellowship in the Department of Hematology and Medical Oncology at the Winship Cancer Institute of Emory University.
Dr. El Rassi's research work is focused on the development of novel approaches to improve the treatment of acute myeloid leukemia, management of sickle cell disease, and iron overload.
Academic Appointment
- Associate Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine
Education
Degrees
- MD from American University of Beirut, Beirut
Research
Publications
-
The Mortality of Adults With Sickle Cell Disease at a Comprehensive Sickle Cell Center.
Eur J Haematol Volume: 114 Page(s): 663 - 671
04/01/2025 Authors: Afranie-Sakyi JA; Randall E; Fasano R; McLemore ML; El Rassi F -
Hematopoietic cell transplant compared with standard care in adolescents and young adults with sickle cell disease.
Blood Adv Volume: 9 Page(s): 955 - 965
03/11/2025 Authors: Walters MC; Eapen M; Liu Y; El Rassi F; Waller EK; Levine JE; Strouse JJ; Antin JH; Parikh SH; Bakshi N -
Long-term quality of life after hematopoietic cell transplant for sickle cell disease in childhood: A STELLAR interim analysis.
Am J Hematol Volume: 99 Page(s): 2037 - 2040
10/01/2024 Authors: Arnold SD; Bakshi N; Ross D; Smith C; Sinha C; Veludhandi A; Dutreuil V; Bai S; Meacham LR; Guilcher G -
Riociguat in patients with sickle cell disease and hypertension or proteinuria (STERIO-SCD): a randomised, double-blind, placebo controlled, phase 1-2 trial.
Lancet Haematol Volume: 11 Page(s): e345 - e357
05/01/2024 Authors: Gladwin MT; Gordeuk VR; Desai PC; Minniti C; Novelli EM; Morris CR; Ataga KI; De Castro L; Curtis SA; El Rassi F -
Enhanced IgG immune response to COVID-19 vaccination in patients with sickle cell disease.
Br J Haematol Volume: 202 Page(s): 937 - 941
09/01/2023 Authors: Nakahara H; Cheedarla N; Verkerke HP; Cheedarla S; Wu S-C; Hendrickson JE; Chang A; McLemore ML; El Rassi F; Roback JD -
Presentations and outcomes among sickle cell disease patients with COVID-19 at a large southern healthcare system.
Expert Rev Hematol Volume: 16 Page(s): 151 - 156
02/01/2023 Authors: Clarke K; Shin YM; Hall MAK; Moussa M; McLemore M; El Rassi F -
A randomized clinical trial of the efficacy and safety of rivipansel for sickle cell vaso-occlusive crisis.
Blood Volume: 141 Page(s): 168 - 179
01/12/2023 Authors: Dampier CD; Telen MJ; Wun T; Brown RC; Desai P; El Rassi F; Fuh B; Kanter J; Pastore Y; Rothman J -
Burden of disease, treatment utilization, and the impact on education and employment in patients with sickle cell disease: A comparative analysis of high- and low- to middle-income countries for the international Sickle Cell World Assessment Survey.
Am J Hematol Volume: 97 Page(s): 1055 - 1064
08/01/2022 Authors: Osunkwo I; James J; El-Rassi F; Nero A; Minniti CP; Trimnell C; Paulose J; Ramscar N; Bailey T; Rajkovic-Hooley O -
Sickle Cell Transplantation Evaluation of Long-term and Late Effects Registry (STELLAR) to Compare Long-term Outcomes After Hematopoietic Cell Transplantation to Those in Siblings Without Sickle Cell Disease and in Nontransplanted Individuals With Sickle Cell Disease: Design and Feasibility Study.
JMIR Res Protoc Volume: 11 Page(s): e36780
07/06/2022 Authors: Krishnamurti L; Arnold SD; Haight A; Abraham A; Guilcher GM; John T; Bakshi N; Shenoy S; Syrjala K; Martin PL -
Sickle Cell Disease and Kidney.
Adv Chronic Kidney Dis Volume: 29 Page(s): 141 - 148.e1
03/01/2022 Authors: Amarapurkar P; Roberts L; Navarrete J; El Rassi F